mhaa4549a
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01877785)
Timeline
Indications
Mechanism of action
- Influenza virusImmunity, passive
Influenza virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mhaa4549a
- mhaa549a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02623322 | Phase 2 | Mar 4, 2016 | Genentech, Roche |
| NCT02293863 | Phase 2 | Jan 14, 2015 | Genentech, Roche |
| NCT02284607 | Phase 1 | Nov 3, 2014 | Genentech, Roche |
| NCT01980966 | Phase 2 | Nov 25, 2013 | Genentech |
| NCT01877785 | Phase 1 | Jul 1, 2013 | Genentech |
Showing 5 of 5 trials
Page 1 / 1